Pharmaceutical

Dren Bio and Novartis link on bispecific antibodies for cancer

Dren Bio has entered a strategic partnership with Novartis Pharma to develop therapeutic bispecific antibodies to treat cancer.

Jul 26, 2024 - 04:00
Dren Bio and Novartis link on bispecific antibodies for cancer
Dren Bio has entered a strategic partnership with Novartis Pharma to develop therapeutic bispecific antibodies to treat cancer.
Read the original article

Tags:

Previous Article

NICE recommends Boehringer’s tenecteplase for NHS stroke care

Next Article

MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CT-080 by First Condor Group for Solid Tumor: Likelihoo...

Oct 3, 2023

Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture

Listen: Biotech’s monkey shortage, the broken generics ...

Mar 30, 2023

STAT+: Pharmalittle: Ohio attorney general accuses PBMs of price fixing; how cost-effectiveness fight could hobble drug price negotiations

STAT+: Pharmalittle: Ohio attorney general accuses PBMs...

Mar 28, 2023